Intellia Therapeutics (NTLA) Change in Account Payables (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Change in Account Payables data on file, last reported at -$1.4 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$1.4 million, up 24.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (up 1108.78% YoY), and the FY2025 annual result was $6.0 million, down 11.96% from the prior year.
• Change in Account Payables slipped to -$1.4 million in Q1 2026 per NTLA's latest filing, from $7.0 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $7.0 million in Q4 2025 and troughed at -$7.7 million in Q3 2023.
• A 5-year average of $547352.9 and a median of $750000.0 in 2022 frame the typical range for Change in Account Payables.
• On a YoY basis, Change in Account Payables climbed as much as 2152.63% in 2023 and fell as far as 374.51% in 2023.
• A 5-year view of Change in Account Payables shows it stood at $750000.0 in 2022, then soared by 425.47% to $3.9 million in 2023, then sank by 63.56% to $1.4 million in 2024, then jumped by 384.61% to $7.0 million in 2025, then tumbled by 120.41% to -$1.4 million in 2026.
• Business Quant data shows NTLA's Change in Account Payables at -$1.4 million in Q1 2026, $7.0 million in Q4 2025, and $3.5 million in Q3 2025.